이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer

2026년 8월 4일 업데이트: Tianjin Medical University Second Hospital

A Prospective, Multicenter, Randomized Controlled Study of Disitamab Vedotin Plus Toripalimab With or Without Pelvic Lymph Node Dissection for Bladder-Sparing Treatment in Patients With cT2-3N0M0 Bladder Urothelial Carcinoma

This is a prospective, multicenter, randomized controlled superiority study designed to evaluate whether the addition of pelvic lymph node dissection improves bladder-intact event-free survival in patients with cT2-3N0M0 bladder urothelial carcinoma receiving bladder-sparing treatment. Eligible patients with HER2 expression of IHC 2+ or higher who decline radical cystectomy will be randomized 1:1 to receive maximal transurethral resection of bladder tumor followed by disitamab vedotin plus toripalimab with or without standardized pelvic lymph node dissection. The primary endpoint is the 2-year bladder-intact event-free survival rate. Secondary endpoints include clinical complete response, partial response, disease progression, overall survival, quality of life, safety, treatment cost, and exploratory biomarker analyses.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

Muscle-invasive bladder cancer is commonly treated with radical cystectomy; however, bladder-sparing strategies are needed for selected patients who decline cystectomy. This study evaluates a bladder-sparing strategy based on maximal transurethral resection of bladder tumor, disitamab vedotin plus toripalimab, and the addition of standardized pelvic lymph node dissection.

Participants will be randomized to receive disitamab vedotin plus toripalimab with or without pelvic lymph node dissection after maximal transurethral resection of bladder tumor. Tumor response will be assessed by imaging, cystoscopy or transurethral resection/biopsy when clinically indicated, and urine cytology. Participants who meet bladder-sparing criteria will enter bladder-intact follow-up according to the protocol. Safety, survival, quality of life, treatment cost, and exploratory biomarkers will also be evaluated.

연구 유형

중재적

등록 (추정된)

114

단계

  • 2 단계
  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, 중국, 300211
        • The Second Hospital of Tianjin Medical University
        • 연락하다:
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  1. Male or female participants aged 18 years or older.
  2. Histologically confirmed bladder urothelial carcinoma.
  3. Clinical stage cT2-3N0M0 according to the AJCC 8th edition TNM staging system.
  4. HER2 expression of IHC 2+ or higher.
  5. Participants who decline radical cystectomy as assessed by the investigator.
  6. Adequate organ function as defined in the study protocol.
  7. Ability to understand and willingness to sign written informed consent.

Exclusion Criteria:

  1. Known allergy or hypersensitivity to disitamab vedotin, toripalimab, their excipients, or other monoclonal antibodies.
  2. Prior radiotherapy for bladder cancer.
  3. Prior anticancer treatment that may affect efficacy assessment, as defined in the study protocol.
  4. Pregnant or breastfeeding women.
  5. Any serious uncontrolled disease or medical condition that, in the investigator's judgment, would make participation inappropriate.
  6. Participation in another interventional clinical trial that may interfere with this study.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Disitamab Vedotin Plus Toripalimab With Pelvic Lymph Node Dissection
Participants will receive maximal transurethral resection of bladder tumor followed by disitamab vedotin plus toripalimab and standardized pelvic lymph node dissection.
Disitamab vedotin will be administered in combination with toripalimab according to the study protocol.
Toripalimab will be administered in combination with disitamab vedotin according to the study protocol.
Maximal transurethral resection of bladder tumor will be performed as part of the bladder-sparing treatment strategy.
Standardized pelvic lymph node dissection will be performed in participants assigned to the PLND arm.
활성 비교기: Disitamab Vedotin Plus Toripalimab Without Pelvic Lymph Node Dissection
Participants will receive maximal transurethral resection of bladder tumor followed by disitamab vedotin plus toripalimab without planned pelvic lymph node dissection.
Disitamab vedotin will be administered in combination with toripalimab according to the study protocol.
Toripalimab will be administered in combination with disitamab vedotin according to the study protocol.
Maximal transurethral resection of bladder tumor will be performed as part of the bladder-sparing treatment strategy.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
2-year Bladder-intact Event-free Survival Rate
기간: 24 months after randomization
The proportion of participants who remain alive with an intact bladder and without muscle-invasive bladder cancer recurrence, regional lymph node recurrence, distant metastasis, radical cystectomy, or bladder cancer-related death at 24 months after randomization.
24 months after randomization

2차 결과 측정

결과 측정
측정값 설명
기간
Clinical Complete Response Rate
기간: After completion of induction treatment, up to 12 weeks
The proportion of participants who achieve clinical complete response, defined as no visible tumor on imaging, no evidence of malignancy on cystoscopy or TURBT/biopsy when clinically indicated, and negative urine cytology. For participants undergoing pelvic lymph node dissection, no lymph node metastasis is required.
After completion of induction treatment, up to 12 weeks
Partial Response Rate
기간: After completion of induction treatment, up to 12 weeks
The proportion of participants with non-muscle-invasive disease, including Ta, T1, or carcinoma in situ, confirmed by urine cytology or pathological biopsy, with no evidence of locally advanced or metastatic disease on imaging.
After completion of induction treatment, up to 12 weeks
Disease Progression Rate
기간: Up to 24 months after randomization
The proportion of participants with disease progression, defined as muscle-invasive bladder cancer confirmed by pathological biopsy, locally advanced disease, regional lymph node recurrence, distant metastasis, or bladder cancer-related death.
Up to 24 months after randomization
Overall Survival
기간: Up to 60 months after randomization
Overall survival is defined as the time from randomization to death from any cause.
Up to 60 months after randomization
Incidence and Severity of Adverse Events
기간: From the first dose through 30 days after the last dose, up to approximately 19 months
The incidence, severity, and relationship to study treatment of adverse events will be assessed according to the Common Terminology Criteria for Adverse Events.
From the first dose through 30 days after the last dose, up to approximately 19 months
Quality of Life Score
기간: Baseline to 24 months after randomization
Quality of life will be assessed using the EORTC QLQ-C30 questionnaire according to the study protocol.
Baseline to 24 months after randomization
Total Treatment Cost
기간: From randomization to the end of follow-up, up to 60 months
Total treatment cost will be calculated from randomization to the final follow-up according to the study protocol.
From randomization to the end of follow-up, up to 60 months

기타 결과 측정

결과 측정
측정값 설명
기간
2-Year Bladder-Intact Event-Free Survival Rate by Baseline HER2 IHC Category
기간: 24 months after randomization
Pretreatment tumor HER2 expression will be assessed by immunohistochemistry and categorized as IHC 2+ or IHC 3+. The percentage of participants meeting the 2-year bladder-intact event-free survival definition will be estimated separately for each HER2 IHC category. Bladder-intact event-free survival is defined as being alive with an intact bladder and without muscle-invasive bladder cancer recurrence, regional lymph node recurrence, distant metastasis, radical cystectomy, or bladder cancer-related death. The unit of measure is percentage of participants.
24 months after randomization

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 8월 1일

기본 완료 (추정된)

2029년 6월 20일

연구 완료 (추정된)

2031년 6월 20일

연구 등록 날짜

최초 제출

2026년 6월 27일

QC 기준을 충족하는 최초 제출

2026년 8월 4일

처음 게시됨 (실제)

2026년 8월 10일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 8월 10일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 8월 4일

마지막으로 확인됨

2026년 6월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • TMU2H-RC48-TORI-MIBC-2026-035

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

IPD 계획 설명

The plan for sharing de-identified individual participant data has not been determined and will be decided after completion of the study, subject to approval by the sponsor, principal investigator, and ethics committee.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .